WCLC 2025 - Posters & ePosters-PT2.12.01 Osimertinib Combined With Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients With Metastatic EGFR-Mutated NSCLC

PT2.12.01 Osimertinib Combined With Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients With Metastatic EGFR-Mutated NSCLC

Asset Subtitle

Regan Memmott

Meta Tag

Speaker Regan Memmott

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy